Should I buy or sell Ionis Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares. View IONS analyst ratings or view top-rated stocks .

What is Ionis Pharmaceuticals' stock price target for 2024?

13 Wall Street analysts have issued 1 year target prices for Ionis Pharmaceuticals' stock. Their IONS share price targets range from $28.00 to $75.00. On average, they expect the company's share price to reach $56.08 in the next year. This suggests a possible upside of 35.5% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts .

How have IONS shares performed in 2024?

Ionis Pharmaceuticals' stock was trading at $50.59 on January 1st, 2024. Since then, IONS stock has decreased by 18.2% and is now trading at $41.40. View the best growth stocks for 2024 here .

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our IONS earnings forecast .

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, February, 21st. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.72. The business earned $325 million during the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative trailing twelve-month return on equity of 90.29%. Ionis Pharmaceuticals's revenue for the quarter was up 113.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.37) earnings per share.

What ETFs hold Ionis Pharmaceuticals' stock?

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include Morningstar US Small Growth (MSGR) , ARK Genomic Revolution ETF (ARKG) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Horizon Kinetics Medical ETF (MEDX) , Invesco Biotechnology & Genome ETF (PBE) , Franklin Genomic Advancements ETF (HELX) , Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC) .

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA) , Micron Technology (MU) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Alibaba Group (BABA) , Alnylam Pharmaceuticals (ALNY) , Biogen (BIIB) , BlackRock (BLK) , Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD) .

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include International Assets Investment Management LLC (0.01%), Diversified Trust Co (0.00%), Sunbelt Securities Inc. (0.00%) and Mather Group LLC. (0.00%). Insiders that own company stock include Allene M Diaz , B Lynne Parshall , Brett P Monia , Brian Birchler , C Frank Bennett , Elizabeth L Hougen , Eric Swayze , Eugene Schneider , Frederick T Muto , Joseph Baroldi, Joseph Klein III , Onaiza Cadoret-Manier , Patrick R O'neil and Spencer R Berthelsen . View institutional ownership trends .

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Free IONS Stock Alerts

$40.95

+0.04 (+0.10%)

(As of 01:28 PM ET)

Compare

Today's Range: $40.94
▼
$41.53
50-Day Range: $40.91
▼
$51.40
52-Week Range: $34.32
▼
$54.44

Volume: 280,228 shs
Average Volume: 1.15 million shs
Market Capitalization: $5.97 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $56.08

Get Ionis Pharmaceuticals alerts:

Ionis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.69 Rating Score
Upside/Downside: 35.5% Upside
$56.08 Price Target
Short Interest: Bearish
7.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: -3.58
Upright™ Environmental Score
News Sentiment: 0.55
Based on 16 Articles This Week
Insider Trading: Selling Shares
$2.56 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.00) to ($3.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

156th out of 914 stocks

Pharmaceutical Preparations Industry

52nd out of 421 stocks

4.3

Analyst's Opinion

Consensus Rating
Ionis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Ionis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
7.11% of the float of Ionis Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Ionis Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in Ionis Pharmaceuticals has recently decreased by 1.55%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ionis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ionis Pharmaceuticals does not have a long track record of dividend growth.

3.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ionis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.
Environmental Sustainability
The Environmental Impact score for Ionis Pharmaceuticals is -3.58.

2.0

News and Social Media Coverage

News Sentiment
Ionis Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Ionis Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
Only 7 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,556,127.00 in company stock.
Percentage Held by Insiders
Only 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($4.00) to ($3.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ionis Pharmaceuticals is -16.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ionis Pharmaceuticals is -16.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ionis Pharmaceuticals has a P/B Ratio of 15.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

IONS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IONS Stock News Headlines

April 18, 2024 | insidertrades.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi Sells 4,006 Shares

April 18, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Lowered by Analyst

April 18, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 18, 2024 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.09 Per Share (NASDAQ:IONS)

April 15, 2024 | nasdaq.com

IONS Quantitative Stock Analysis

April 12, 2024 | msn.com

Wolfe upgrades Ionis to outperform, cites upcoming catalysts

April 12, 2024 | americanbankingnews.com

Wolfe Research Upgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Outperform

April 11, 2024 | investing.com

Ionis Pharmaceuticals stock upgraded to Outperform

April 18, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

April 11, 2024 | investing.com

Ionis Pharmaceuticals stock upgraded to Outperform

April 10, 2024 | americanbankingnews.com

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Increased to $75.00 by Analysts at Oppenheimer

April 10, 2024 | americanbankingnews.com

Ionis Pharmaceuticals' (IONS) Buy Rating Reaffirmed at Needham & Company LLC

April 10, 2024 | americanbankingnews.com

Ionis Pharmaceuticals (NASDAQ:IONS) Receives Outperform Rating from William Blair

April 9, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)

April 8, 2024 | markets.businessinsider.com

Ionis Pharmaceuticals Faces Sell Rating Amid Weak Clinical Results and Rising Competition

April 8, 2024 | markets.businessinsider.com

Buy Rating on Ionis Pharmaceuticals: Promising Clinical Data and Strategic Market Positioning for Olezarsen

April 8, 2024 | msn.com

Ionis experimental drug meets key goal in familial chylomicronemia study

April 8, 2024 | finanznachrichten.de

Ionis Pharmaceuticals, Inc.: Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

April 8, 2024 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Rating of "Moderate Buy" by Brokerages

April 7, 2024 | prnewswire.com

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

April 1, 2024 | prnewswire.com

Ionis to present at upcoming investor conferences

March 28, 2024 | prnewswire.com

Ionis to hold olezarsen Phase 3 data webcast

March 25, 2024 | prnewswire.com

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting

March 22, 2024 | finance.yahoo.com

Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?

March 17, 2024 | ca.finance.yahoo.com

IONS Oct 2024 50.000 put

March 16, 2024 | msn.com

NASH drug market expected to surpass $48B by 2035

March 16, 2024 | finance.yahoo.com

IONS Apr 2024 75.000 call

See More Headlines

Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:IONS
CUSIP: 46433010
CIK: 874015
Web: www.ionispharma.com
Phone: (760) 931-9200
Fax: 760-603-2700
Employees: 927
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $56.08
High Stock Price Target: $75.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +37.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.69
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-366,290,000.00
Net Margins: -46.32%
Pretax Margin: -42.40%
Return on Equity: -90.29%
Return on Assets: -12.39%

Debt

Debt-to-Equity Ratio: 3.18
Current Ratio: 5.90
Quick Ratio: 5.83

Sales & Book Value

Annual Sales: $788 million
Price / Sales: 7.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.70 per share
Price / Book: 15.15

Miscellaneous

Outstanding Shares: 145,750,000
Free Float: 141,890,000
Market Cap: $5.96 billion
Optionable: Optionable
Beta: 0.39

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Brett P. Monia Ph.D. (Age 63)
Founder, CEO & Director
Comp: $1.71M
Ms. Elizabeth L. Hougen M.A. (Age 62)
M.B.A., M.S., Executive VP of Finance & CFO
Comp: $1.02M
Ms. B. Lynne Parshall Esq. (Age 70)
J.D., Senior Strategic Advisor & Director
Comp: $334.64k
Dr. Richard S. Geary Ph.D. (Age 66)
Executive VP & Chief Development Officer
Comp: $946.26k
Mr. Joseph T. Baroldi M.A. (Age 45)
M.B.A., M.S., Executive VP & Chief Business Officer
Comp: $815.87k
Mr. Darren Gonzales
Chief Accounting Officer & Senior VP
Dr. C. Frank Bennett BSc (Age 67)
Ph.D., Executive VP & Chief Scientific Officer
Comp: $651.64k
Mr. D. Wade Walke Ph.D.
Senior Vice President of Investor Relations
Mr. Patrick R. O'Neil Esq. (Age 50)
Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary
Comp: $815.69k
Ms. Hayley Soffer
Vice President of Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IONS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IONS shares.
View IONS analyst ratings or view top-rated stocks.
What is Ionis Pharmaceuticals' stock price target for 2024?: 13 Wall Street analysts have issued 1 year target prices for Ionis Pharmaceuticals' stock. Their IONS share price targets range from $28.00 to $75.00. On average, they expect the company's share price to reach $56.08 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.
How have IONS shares performed in 2024?: Ionis Pharmaceuticals' stock was trading at $50.59 on January 1st, 2024. Since then, IONS stock has decreased by 18.2% and is now trading at $41.40.
View the best growth stocks for 2024 here.
When is Ionis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IONS earnings forecast.
How were Ionis Pharmaceuticals' earnings last quarter?: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, February, 21st. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.72. The business earned $325 million during the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative trailing twelve-month return on equity of 90.29%. Ionis Pharmaceuticals's revenue for the quarter was up 113.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.37) earnings per share.
What ETFs hold Ionis Pharmaceuticals' stock?: ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Invesco Biotechnology & Genome ETF (PBE), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC).

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?: Ionis Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.0 million-, compared to the consensus revenue estimate of $636.4 million.
What other stocks do shareholders of Ionis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).
Who are Ionis Pharmaceuticals' major shareholders?: Ionis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include International Assets Investment Management LLC (0.01%), Diversified Trust Co (0.00%), Sunbelt Securities Inc. (0.00%) and Mather Group LLC. (0.00%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Eugene Schneider, Frederick T Muto, Joseph Baroldi, Joseph Klein III, Onaiza Cadoret-Manier, Patrick R O'neil and Spencer R Berthelsen.
View institutional ownership trends.
How do I buy shares of Ionis Pharmaceuticals?: Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IONS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis

Ionis Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ionis Pharmaceuticals Stock (NASDAQ:IONS)

IONS Stock Price History

IONS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IONS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™